Introduction
Patients and Methods
Study Design and Conduct
Study Population
Intervention
Evaluation
Study Endpoints
Statistical Analysis
Results
Patients
Age, mean (range) | 67 (50–83) |
PSA at baseline, mean (range) (ng/mL) | 45.3 (5–3603) |
ECOG performance status | |
ECOG 0, N (%) | 49 (80.3) |
ECOG 1, N (%) | 11 (18.0) |
ECOG 2, N, (%) | 1 (1.6) |
Previous therapy, N (%) | |
Prostatectomy | 22 (36.1) |
Radiation | 35 (57.4) |
Hormone therapy | 61 (100) |
Metastases at baseline, N (%) | |
Bone metastases only | 33 (54.1) |
Bone metastases | |
+ lung/liver | 2 (3.3) |
+ lung | 1 (1.6) |
+ liver | 2 (3.3) |
+ nodes | 13 (21.3) |
Nodes only | 6 (9.8) |
Locally advanced disease | 4 (6.6) |
PSA Response
Secondary Endpoints
Safety
Patients N (%) | AE N (%) | |
All adverse events | 65 (100) | 947 (100) |
With suspected relation to study drug | 64 (98.5) | 545 (57.6) |
Leading to dose adjustment or temporary interruption | 50 (76.9) | 131 (13.8) |
Leading to permanent discontinuation | 15 (23.1) | 27 (2.9) |
Requiring concomitant medication/non-drug therapy | 62 (95.4) | 381 (40.2) |
All serious adverse events | 27 (41.5) | 98 (10.3) |
Deaths | 4 (6.2) | |
With suspected relation to study drug | 14 (21.5) | 32 (3.4) |
Leading to permanent discontinuation | 5 (7.7) | 11 (1.2) |
Patients N (%) | ||
Frequent adverse events (>20 %)a
| All grades | Grade ≥3 |
Peripheral edema | 38 (58.5) | 1 (1.5) |
Nausea | 30 (46.2) | 3 (4.6) |
Fatigue | 29 (44,6) | 8 (12.3) |
Diarrhea | 29 (44.6) | 0 (0.0) |
Dyspnea | 26 (40.0) | 5 (6.2) |
Edema | 25 (38.5) | 0 (0.0) |
Anemia | 24 (36.9) | 4 (6.2) |
Leukopenia | 20 (30.8) | 5 (7.7) |
Vomiting | 19 (29.2) | 2 (3.1) |
Muscle cramps | 16 (24.6) | 1 (1.5) |
Facial edema | 15 (23.1) | 2 (3.1) |
Increased weight | 14 (21.5) | 0 (0.0) |
Increased blood lactate dehydrogenase | 14 (21.5) | 1 (1.5) |